Drugs / Bevasizumab
last change Dec 2010 re-read 2 minutes ago

Bevasizumab

Developed for
central retinal vein occlusion

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01178697 Comparator Jan → Sep 2010 central retinal vein occlusion Shahid Beheshti University of Medical Sciences Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Bevasizumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT01178697
Route Intravitreal Intravitreal, 1.25 mg, 3 times, one month apart.” NCT01178697